KR960702849A - 사람유래 종양세포 증식저해 인자 - Google Patents

사람유래 종양세포 증식저해 인자 Download PDF

Info

Publication number
KR960702849A
KR960702849A KR1019950705398A KR19950705398A KR960702849A KR 960702849 A KR960702849 A KR 960702849A KR 1019950705398 A KR1019950705398 A KR 1019950705398A KR 19950705398 A KR19950705398 A KR 19950705398A KR 960702849 A KR960702849 A KR 960702849A
Authority
KR
South Korea
Prior art keywords
tumor cell
human
cell proliferation
derived
bacillus brevis
Prior art date
Application number
KR1019950705398A
Other languages
English (en)
Other versions
KR100313736B1 (ko
Inventor
토시 고무라사키
키요시 나카자와
히토시 도요다
마사요시 다카하시
다이수케 우치다
카즈노리 하나다
시게조 우다카
Original Assignee
우에하라 아키라
다이쇼 세야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 우에하라 아키라, 다이쇼 세야쿠 가부시키가이샤 filed Critical 우에하라 아키라
Publication of KR960702849A publication Critical patent/KR960702849A/ko
Application granted granted Critical
Publication of KR100313736B1 publication Critical patent/KR100313736B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

마우스 유래 종양세포 증식저해인자를 코드하는 DNA 단편을 DNA 프로우브로서 사용하여 사람 결장암세포 유래의 cDNA 라이브러리로부터 사람유래의 신규한 종양세포 증식저해인자를 코드하는 DNA 단편을 얻을 수 있다. 바실러스 브레비스균 유래의 프로모터, 바실러스 브레비스균 유래의 시그날 펩티드 및 그의 하류에 사람 종양세포 증식저해인자를 코드하는 DNA 단편을 함유하는 발현 플라스미드를 구축하고, 이를 이용하여 바실러스 브레비스균을 형질전환하고, 얻어진 형질전환체를 배양함으로서 신규 저해인자를 균체외로 분비시킬 수 있고, 효율 좋게 이 신규 저해인자를 제조하는 것이 가능하다.

Description

사람유래 종양세포 증식저해 인자
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 마우스 유래 종앙세포 증식저해 인자를 코드하는 DNA 단편의 염기 배열 및 아미노산 배열을 나타낸다,
제2도는 서던 하이브리다이제이션(Southern hybridization)에 의한 사람태반 염색체 DNA 단편의 해석도, 즉 오토래디오그래피이다,
제3도는 사람유래 종양세포 증식저해 인자의 일부를 코드하는 염색체 DNA 단편의 개략도(a), 사람유래 종양세포 증식저해 인자의 일부와 마우스유래 종양세포 증식저해 인자의 전구체의 cDNA 단편의 일부와의 염기배열의 비교(b), 마우스 유래 종양세포 증식저해 인자의 전구체의 일부와의 아미노산 배열의 비교(c)를 난타낸다.

Claims (7)

  1. 식(I)로 표시되는 아미노산 배열을 갖는 사람유래 종양세포 증식저해 인자
  2. 청구범위 제1항의 사람유래 종양세포 종양저해 인자를 코드하는 DNA 단편.
  3. 제2항에 있어서, 식(2)로 표시되는 염기 배열을 갖는 DNA 단편.
  4. 바실러스 브레비스균 유래의 프로모터, 바실러스 브레비스균 유래의 시그날 펩티드를 코드하는 DNA 단편, 및 제2항 또는 제3항의 DNA 단편을 함유하는 DNA 배열.
  5. 제4항의 DNA 배열을 함유하는 사람유래 종양세포 증식저해인자의 발현 플라스미드.
  6. 제5항의 발현 플라스미드로 형질전환된 바실러스 브레비스균.
  7. 제6항의 바실러스 브레비스균을 배양하여 사람유래 종양세포 증식저해인자를 발현시키고, 균체외로 분비시킨 후, 이어서 이 배양액으로부터 사람유래 종양세포 증식저해인자를 회수하는 사람 종양세포 증식저해인자의 유전자 공학적 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950705398A 1993-06-04 1994-06-02 사람유래종양세포증식저해인자 KR100313736B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP13485593 1993-06-04
JP134854/1993 1993-06-04
JP13485493 1993-06-04
JP134855/1993 1993-06-04
PCT/JP1994/000895 WO1994029340A1 (fr) 1993-06-04 1994-06-02 Facteur d'inhibition de la proliferation de cellules tumorales d'origine humaine

Publications (2)

Publication Number Publication Date
KR960702849A true KR960702849A (ko) 1996-05-23
KR100313736B1 KR100313736B1 (ko) 2002-03-21

Family

ID=26468834

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950705398A KR100313736B1 (ko) 1993-06-04 1994-06-02 사람유래종양세포증식저해인자

Country Status (6)

Country Link
US (1) US5783417A (ko)
EP (1) EP0703242A1 (ko)
KR (1) KR100313736B1 (ko)
AU (1) AU685124B2 (ko)
CA (1) CA2164295A1 (ko)
WO (1) WO1994029340A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1761682A (zh) * 2003-03-14 2006-04-19 大正制药株式会社 单克隆抗体与产生该单克隆抗体的杂交瘤
CA2536146A1 (en) * 2003-08-19 2005-02-24 Agos Biotech Ltd. Splice variants of erbb ligands, compositions and uses thereof
NZ576855A (en) 2006-10-12 2012-08-31 Forerunner Pharma Res Co Ltd Diagnosis and treatment of cancer using anti-ereg antibody
JP5808052B2 (ja) 2009-05-29 2015-11-10 中外製薬株式会社 Ｅｇｆファミリーリガンドのアンタゴニストを成分とする医薬組成物
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524145A (en) * 1984-09-04 1985-06-18 Bristol-Myers Company 4'-Deschlororebeccamycin pharmaceutical composition and method of use
JP2784272B2 (ja) * 1990-06-06 1998-08-06 大正製薬株式会社 腫瘍細胞増殖阻害因子
ATE177146T1 (de) * 1991-12-05 1999-03-15 Taisho Pharmaceutical Co Ltd Dna-fragment kodierend für einen tumorzell- proliferationsinhibitierenden faktor

Also Published As

Publication number Publication date
AU6856294A (en) 1995-01-03
EP0703242A1 (en) 1996-03-27
KR100313736B1 (ko) 2002-03-21
CA2164295A1 (en) 1994-12-22
WO1994029340A1 (fr) 1994-12-22
AU685124B2 (en) 1998-01-15
US5783417A (en) 1998-07-21

Similar Documents

Publication Publication Date Title
ES2227669T3 (es) Elementos de secuencia que aumentan la expresion (ease) para sistemas de expresion de eurocariotas.
DK1623990T3 (da) Sammensætninger og fremgangsmåder til tumorbehandling
LV12814B (lv) Cikliskas gmp-saistošas, cikliskas gmp-specifiskas fosfodiesterāzes materiāli un producēšanas paņēmieni
DK1032668T3 (da) Fibroblast vækstfaktor 19
DK0941318T5 (da) Håndvægtformede konstruerede ekspressionssystemer til genterapi
WO2000053755A3 (en) Compositions and methods for the treatment of tumor
ATE239036T1 (de) Rekombinantes core-streptavidin
ES2332916T3 (es) Composiciones y metodo para el tratamiento de tumores.
DE69738254D1 (de) Methode zur bereitstellung von dna sequenzen
ATE384787T1 (de) Tripeptidyl-aminopeptidase
KR960702849A (ko) 사람유래 종양세포 증식저해 인자
ES2324876T3 (es) Composiciones y metodos para el diagnostico de tumores.
Xu et al. Polymorphic tandem DNA repeats activate the human telomerase reverse transcriptase gene
ATE399862T1 (de) Menschliche nukleinsäuresequenz aus prostatatumorgewebe
Desseyn et al. Characterization of mouse muc6 and evidence of conservation of the gel-forming mucin gene cluster between human and mouse
DE69323199D1 (de) Gen für die ataxia-telangiectasia komplementationsgruppe d
KR950032622A (ko) 전사 인자 에이피알에프(aprf)
WO2000037640A3 (en) Compositions and methods for the treatment of tumor
Sémat et al. Sequence analysis of murine cytokeratin endo A (n° 8) cDNA. Evidence for mRNA species initiated upstream of the normal 5′ end in PCC4 cells
ATE288488T1 (de) Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen
Aziz-Aloya et al. Promoter elements and alternative splicing in the human ACHE gene
Fournier et al. Differential transcription of multiple copies of a silk worm gene encoding tRNA1Gly
Baumgartner et al. Drosophila ribosomal protein S19 cDNA sequence.
Gatti et al. Variation with sex of irradiation-induced chromosome damage in somatic cells of Drosophila melanogaster
Weinberg et al. Histone gene heterogeneity in the sea urchin Strongylocentrotus purpuratus

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee